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Most patients now receiving a haematopoietic stem cell transplant (HSCT) for chronic myeloid leukaemia
(CML) have been treated with ﬁrst and second line TKIs pre-HSCT, raising concerns that these patients
will have more resistant disease and accumulated greater toxicity from sequential lines of therapy,
potentially compromising their outcome. We outline a series of 9 patients treated with imatinib then
second generation TKIs for CML followed by HSCT and compare their outcomes with patients receiving
imatinib-only pre-HSCT. Our case series demonstrates that second line and sequential tyrosine kinase
inhibitors followed by HSCT is a safe and effective therapeutic approach for high risk CML.
& 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Case series
Despite the indisputable success of tyrosine kinase inhibitors
for chronic myeloid leukaemia (CML), there remains a subset of
patients for whom haematopoietic stem cell transplantation
(HSCT) remains necessary. A recent follow up of the International
Randomised Study of Interferon and STI571 (IRIS) Study identiﬁed
that almost 30% of patients discontinued imatinib because of
suboptimal response or poor tolerance of therapy1,2. Furthermore,
we know that patients presenting with advanced phase CML
respond poorly to TKIs3. Data on imatinib use pre-transplant has
not shown any deleterious effect4 but data on second generation
TKIs is sparse5. Although CML is exquisitely sensitive to the graft-
versus leukaemia (GVL) effect of HSCT, toxicity of this procedure
remains a concern. A further concern is the likelihood of HSCT
success in patients who have failed successive targeted therapies
and have potentially acquired more resistant disease. We report
our single centre experience of the impact of second generation
TKIs on the outcomes of allogeneic HSCT for CML, and compare
these outcomes to our previously published historic controls6.
Between March 2006 and December 2011, 9 patients with
imatinib-resistant CML were treated with allogeneic HSCT following
second generation TKI at the Beatson West of Scotland Cancer
Centre. There were 7 males and median age at HSCT was 50 yearsf).
-NC-ND license.(range 34–64 years). Four patients were in accelerated phase at
diagnosis and 5 in chronic phase. Four patients had primary
imatinib resistance and 5 had lost their response. Mutational
analysis was positive in 1 patient (a binding site mutation not
previously reported). At commencement of second generation TKI
7 patients were in chronic phase and 2 were in blast crisis.
Nilotinib was used as a single agent in 1 patient, dasatinib in
4 patients; with sequential dasatanib and nilotinib use in
4 patients. The best response to second generation TKI was
complete cytogenetic response (CCyR) in 5 patients, partial cyto-
genetic response (PCyR) in 1 and a complete haematological
response (CHR) in 3 patients. These best responses were not all
sustained at the time of HSCT (see Table 1). The median time on
second generation TKI was 7 months (range 4–28 months) and in
the majority of patients the TKI was stopped 2 weeks prior to
HSCT. Conditioning was myeloablative in 5 patients and conditioning
regimes varied according to patients' age and suitability for
myeloablative or reduced intensity regimens. For patients receiving
reduced intensity regimens with a history of lymphoid blast crisis
busulphan was used instead of melphalan. Graft versus host disease
prophylaxis was with cyclosporin (2.5 mg/kg day −2,1.25mg/kg day −1
and levels maintained at 200–300 mcg/l until dose reduction) and
methotrexate 10mg/m2 on day +1, +3 and +6. In all peripheral blood
stem cell grafts were used. Patient characteristics are summarised
in Table 1.
All patients engrafted; 1 patient (Patient 6) developed secondary
graft rejection following an A antigen mismatched graft from a male
sibling and went on to receive a VUD HSCT with a female donor.
Table 1
Patient and treatment characteristics.
Patient Age
at
HSCT
Sex Disease
phase at
diagnosis
Indication for HSCT Months
to HSCT
Time on
imatinib:
best
response
2nd generation TKI use: best
response and molecular
response pre-HSCT
Disease
phase
pre-HSCT
Donor type and
matching
Conditioning
1 61 M AP Previous AP including clonal
evolution
23 18 months:
CCyR
Nilotinib 4 months: CCyR 2nd CP VUD 10/10 match Flu/Bu/
Campath
2 64 M CP 11 resistance 1st generation
TKI, 21 resistance 2nd
generation TKI
27 20 months:
PCyR
1.Dasatinib 3 months: CCyR 2nd CP SIB FLu/Mel/
Campath2. Nilotinib 3 months: CHR 10/10 match
3 35 M AP Previous AP, 21 resistance 1st
and 2nd generation TKis
29 19 months:
MCyR
Dasatinib 8 months: CCyR 2nd CP VUD TBI/Cyclo/
CampathLost CCyR and in CHR pre-
HSCT
10/10 match
4 52 M CP 11reistance 1st and 2nd
generation TKIs
22 9 months:
CHR only
1.Dasatinib 8 months: CHR
only
1st CP VUD Flu/Mel/
Campath
2. Nilotinib 5 months: CHR
only
10/10 match
5 50 M AP Previous myeloid blast crisis,
11 resistance to 1st and 2nd
generation TKIs
10 5 months:
CHR only
1.Nilotinib: 3 months: disease
progression
2nd CP VUD Treo/Cyclo/
Campath
2.Dasatinib 3 months: PCyR
(pleural effusions)
10/10 match
6 50 F AP Previous lymphoid blast crisis 21 16 months:
CCyR
Dasatinib 4 months: CCyR 2nd CP *1. SIB 9/10 match
Ć(‘A’ antigen
mismatch)
1. Treo/
Cyclo/
Campath
2. VUD 10/10
match
2. Flu/Bu/
Campath
7 34 M CP Previous AP and poor
tolerance TKIs
36 7 months:
PHR
Dasatinib 28 months: CCyR 2nd CP Volunteer
unrelated donor
TBI/Cyclo/
Campath
10/10 match
8 41 M CP Previous myeloid blast crisis 25 18 months:
CHR
Dasatinib 6 months: CHR only 3rd CP VUD Flu/Mel
10/10 match Campath
9 45 F CP 11 resistance to 1st and 2nd
generation TKIs
26 14 months:
CHR
1. Nilotinib 9 months: CHR
only
AP VUD Treo/Cyclo/
Campath
2. Dasatinib 2 months: disease
progression
9/10 match Ć
(‘A’ antigen
mismatch)
Abbreviations: HSCT indicates haematopoietic stem cell transplant, CP indicates chronic phase; AP accelerated phase; VUD indicates volunteer unrelated donor; SIB is a
sibling donor; CCyR is complete cytogenetic response, MCyR is a major cytogenetic response, PCyR is partial cytogenetic response, CHR is complete haematological response,
PHR is partial haematological response (or incomplete haematological response)
Flu/Bu/Campath is Fludarabine (30 mg/m2 day 7 to 3)/Cyclophosphamide (60 mg/kg day 3 and 2) and alemtuzumab (20 mg day 8, 10 mg bd day 7 to day 4); Flu/Mel/
Campath is Fludarabine (30 mg/m2 day 7 to 3)/Melphalan (140 mg/m2 day 2) and alemtuzumab, (20 mg day 8, 10 mg bd day 7 to 4) TBI/Cyclo/Campath is total body
irradiation (1440 Gy in 8 fractions)/Cyclophosphamide (60 mg/kg day 3 and 2)and alemtuzumab(10 mg, day 5 to 1) Treo/Cyclo/Campath is Treosulphan (14 g/m2),
Cyclophosphamide (60 mg/kg day 3 and 2) and alemtuzumab (20 mg day 8, 10 mg bd day 7 to 4).
n This patient received 2 times HSCT owing to secondary graft failure of ﬁrst HSCT which was an ‘A’ antigen mismatch.
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infections occurred in 6 patients prior to engraftment, and all
responded to antibiotics. Seven out of 9 patients are alive at a
median follow up of 46 months post HSCT (range 6–82 months).
Patient 6 presented in chronic phase and progressed to lymphoid
blast crisis with CNS disease on imatinib. She was subsequently
treated with vincristine and prednisolone and 1 cycle of high dose
methotrexate combined with dasatinib and obtained a complete
morphological remission. She died of sepsis and chronic GVHD,
in complete molecular remission (CMR), following her second
allograft. Patient 8 was transplanted post second myeloid blast
crisis (in 3rd responsive phase), and relapsed back into blast crisis
3 months post HSCT and died 5 months post-HSCT. The median times
to engraftment, complications of HSCT, use of donor lymphocyte
infusions (DLI) and outcomes are summarised in Table 2.
By deﬁnition, patients intolerant or resistant to TKIs will have
higher EBMT scores than historical controls7. In 2008 our centre
published a case series of 14 patients who had achieved a CCyR
with imatinib and then went on to have a reduced intensity
conditioned allograft followed by DLI to eradicate minimal residual
disease in patients with a BCR-ABL:ABL 40.02%6. Despite this
group of patients having an inherently better risk proﬁle (median
EBMT score 2.5 versus 5 in this cohort)—engraftment times,toxicities from HSCT and outcomes from HSCT were similar.
Engraftment in the imatinib only group was a median of 10 days
to neutrophils 40.5109, versus 14 days in the second genera-
tion TKI group, and time to platelets 420109 was 10 days and
11 days respectively. GVHD was more frequent in the imatinib only
group (57% of patients) compared with the second-generation TKI
cohort (44%; not signiﬁcant). In the imatinib only group all
patients had at least a major molecular response (MMR) with
8 out of 14 patients achieving a complete molecular response
(CMR). In the second generation TKI group 1 patient died of
relapsed blast crisis and a second has incurred cytogenetic relapse
at least in part due to poor compliance. The other surviving
patients all achieved at least a MMR, with 4 patients obtaining a
CMR. There was 1 treatment related death in each group.
The role of second generation TKIs post HSCT remains unde-
ﬁned. Relapse is the principal cause of treatment failure post HSCT.
CML is exquisitely sensitive to DLI and this can be an effective
means of treating molecular or cytogenetic relapse, but carries
with it incumbent risks of GVHD8. Imatinib has previously been
shown to be an effective therapy for post transplant relapse9 and
there is therefore a rationale for use of a TKI in high-risk patients
post HSCT in a prophylactic setting10. It is intuitive that in
these imatinib resistant/intolerant patients a second generation
Table 2
Summary of engraftment, HSCT complications and outcomes.
Patient Days to
ANC4500/
mm3
Days to
plts420,000/
mm3
Acute
GVHD
Chronic
GVHD
Other toxicity DLI Second generation TKI use post HSCT Current
status
F/U
1 12 9 No Yes No No NiIotinib commenced at day +38 for 2weeks. Stopped due
to cytopenias. Recommenced at+4 months and stopped at
+7 months owing to recurrent cytopenias despite GCSF
CMR 54
Months
2 9 9 No No Likely CMV
pneumonitis
No Dasatinib commenced day +50. Stopped after 2 weeks
owing to GI side effects.
MMR 44
Months
3 17 8 No No PTLDc Yes Total
dose:
0.52107/
kg
1. Dasatinib started day+86, stopped after 6 weeks owing
to cytopenias
MMR 53
Months
2. Nilotinib then used for 4 months but stopped due to
cytopenias despite GCSF
4 11 11 No Yes Idiopathic
thrombocytopenic
purpura
Yes Total
dose:
6.81107/
kg
Nilotinib started at day+88 but stopped after 4 weeks
owing to cytopenias despite GCSF
CMR 51
Months
5 18 a No No Seizures Yes Total
dose:
0.61 07/
kg
Nilotinib started at day +74, stopped after 3 months owing
to deranged LFTs
CMR 46
Months
6b 1.14 2.77 a 1. No
2.
Yesb
1. No 2.
Yesb
No No Dasatinib started day +56 for 5 months and stopped
owing to secondary graft failure
Died 21
Months
7 14 12 No No No No Nil (poor compliance) with previous TKIs CMR 82
Months
8 11 16 No No No No Nil (relapsed blast crises) Diedd 6
Months
9 19 11 Yes Yes PTLDc No Bosutinib started day+84, remains on at +8 months but
poor compliance
Relapsede 13
Months
Abbreviations: ANC is absolute neutrophil count, GVHD is graft versus host disease, DLI is donor lymphocyte infusion, TKI is tyrosine kinase inhibitor, HSCT is haematopoietic
stem cell transplant, GI is gastrointestinal, CMV is cytomegalovirus, PTLD is post transplant lymphoproliferative disorder, LFTs is liver function tests, MMR is major molecular
response and CMR is complete molecular response.
a Patients on LMWT heparin – thus platelet count maintained 440 with transfusion throughout cytopenic phase.
b This patient received 2 times HSCT owing to secondary graft failure of initial HSCT.
c Both patients with PTLD responded to single agent rituximab.
d Relapsed blast crisis 3 months post HSCT (patient transplanted post second blast crisis in 3rd responsive phase).
e Cytogenetic relapsed likely secondary to poor compliance with post-HSCT TKIs, initial molecular relapse unable to be controlled with DLI owing to concurrent GVHD.
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tolerated post HSCT with frequent haematologic and gastrointestinal
toxicities. In addition, drug interactions can be a signiﬁcant problem
in the post HSCT period with the majority of patients on multiple
medications including antibiotics and immunosuppressants.
In this cohort a second generation TKI post HSCT was
attempted post HSCT in 7 patients (see Table 2). It was intended
to commence TKIs approximately 4 weeks post engraftment
routinely, regardless of BCR-ABL transcript number. TKI selection
was based on previous response to TKI pre-HSCT and commenced
post HSCT at a median of +65 days (range +38 to +88 days) for a
median of 14 weeks (range 2–32 weeks) but all ultimately were
stopped owing to toxicities, predominantly cytopenias. Patient
9 received bosutinib (having proven refractory to all other second
generation TKIs pre-HSCT) for increasing BCR-ABL transcript
numbers post HSCT and initially achieved a MMR (not a candidate
for DLI owing to concurrent grade II GVHD) but has since suffered
a cytogenetic relapse owing to poor compliance not caused
by toxicities. In the context of our high rates of MMRs without
successful use of prophylactic second generation TKIs post
HSCT, we have now abandoned prophylactic second generation
TKI usage. At our centre, post transplant TKIs are now considered
for mixed chimerism and increasing BCR-ABL transcripts as a
bridge to DLI or in patients with GVHD for whom DLI is
inappropriate.
In conclusion, we demonstrate that HSCT for CML even in this
case series of notably high-risk patients remains an effective and
comparatively safe therapeutic tool for these patients in whom
treatment options are limited. Furthermore, second generationTKIs should only be considered in selected patients post HSCT due
to toxicities.Acknowledgements
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